{"groups":[{"description":"Cabozantinib (XL184) 60 mg tablet once daily\n\nCabozantinib tablets","id":"FG000","title":"Cabozantinib (XL184)"},{"description":"Oral cabozantinib-matched placebo tablet once daily\n\nPlacebo tablets","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"38"}],"type":"Clinical Deterioration"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"152"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"No Study Treatment Given"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"470"},{"groupId":"FG001","numSubjects":"237"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"26"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"397"},{"groupId":"FG001","numSubjects":"211"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"First patient enrolled: 26 September 2013, Data cut-off date: 01 June 2017"}